Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 4 | 2013 | 342 | 0.880 |
Why?
|
| Interferons | 3 | 2013 | 126 | 0.810 |
Why?
|
| Antiviral Agents | 5 | 2021 | 767 | 0.730 |
Why?
|
| Ribavirin | 3 | 2010 | 86 | 0.700 |
Why?
|
| Kupffer Cells | 1 | 2019 | 18 | 0.620 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2019 | 57 | 0.590 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2019 | 108 | 0.570 |
Why?
|
| Liver Transplantation | 5 | 2017 | 1039 | 0.540 |
Why?
|
| Calcineurin Inhibitors | 1 | 2017 | 29 | 0.530 |
Why?
|
| Everolimus | 1 | 2017 | 50 | 0.530 |
Why?
|
| Liver Cirrhosis | 5 | 2020 | 842 | 0.480 |
Why?
|
| Liver | 2 | 2019 | 1749 | 0.460 |
Why?
|
| Hepatitis B | 2 | 2021 | 161 | 0.460 |
Why?
|
| Graft Survival | 1 | 2017 | 538 | 0.450 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2014 | 933 | 0.420 |
Why?
|
| Graft Rejection | 1 | 2017 | 590 | 0.420 |
Why?
|
| Kidney Diseases | 1 | 2017 | 480 | 0.400 |
Why?
|
| Retinal Diseases | 1 | 2013 | 172 | 0.360 |
Why?
|
| Lypressin | 1 | 2010 | 16 | 0.340 |
Why?
|
| Hepatorenal Syndrome | 1 | 2010 | 28 | 0.320 |
Why?
|
| Immunosuppressive Agents | 4 | 2021 | 651 | 0.320 |
Why?
|
| Vasoconstrictor Agents | 1 | 2010 | 137 | 0.310 |
Why?
|
| Hepatitis B virus | 1 | 2009 | 130 | 0.310 |
Why?
|
| Sarcoidosis | 1 | 2008 | 60 | 0.300 |
Why?
|
| Enterocolitis, Neutropenic | 1 | 2007 | 2 | 0.290 |
Why?
|
| Fibrosis | 1 | 2009 | 438 | 0.280 |
Why?
|
| Fatty Liver | 1 | 2008 | 188 | 0.270 |
Why?
|
| Bariatric Surgery | 1 | 2008 | 120 | 0.260 |
Why?
|
| Polyethylene Glycols | 1 | 2007 | 240 | 0.260 |
Why?
|
| Interferon-alpha | 1 | 2007 | 242 | 0.250 |
Why?
|
| Liver Diseases | 1 | 2008 | 368 | 0.230 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 1318 | 0.220 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 27 | 0.170 |
Why?
|
| Hepatitis C | 2 | 2017 | 367 | 0.160 |
Why?
|
| Skin Diseases | 1 | 2021 | 130 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 1122 | 0.150 |
Why?
|
| Humans | 18 | 2021 | 125667 | 0.140 |
Why?
|
| Lip Neoplasms | 1 | 2017 | 4 | 0.140 |
Why?
|
| Ethanol | 1 | 2019 | 163 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 2 | 2017 | 507 | 0.140 |
Why?
|
| Liver Failure | 1 | 2017 | 89 | 0.130 |
Why?
|
| Kidney Function Tests | 1 | 2017 | 129 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 115 | 0.130 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 1175 | 0.120 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 294 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2014 | 12420 | 0.120 |
Why?
|
| Sirolimus | 1 | 2017 | 227 | 0.120 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2020 | 398 | 0.120 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 635 | 0.120 |
Why?
|
| Models, Statistical | 1 | 2017 | 472 | 0.120 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 1248 | 0.110 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2014 | 23 | 0.110 |
Why?
|
| Niacinamide | 1 | 2014 | 23 | 0.110 |
Why?
|
| Liver Function Tests | 2 | 2017 | 101 | 0.110 |
Why?
|
| Metabolomics | 1 | 2017 | 423 | 0.110 |
Why?
|
| Phenylurea Compounds | 1 | 2014 | 49 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 512 | 0.100 |
Why?
|
| Biopsy | 3 | 2017 | 1241 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 2918 | 0.100 |
Why?
|
| Length of Stay | 1 | 2017 | 1313 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 373 | 0.090 |
Why?
|
| Catheter Ablation | 1 | 2014 | 233 | 0.090 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2019 | 702 | 0.090 |
Why?
|
| Jejunal Neoplasms | 1 | 1991 | 5 | 0.090 |
Why?
|
| Tuberculosis, Gastrointestinal | 1 | 1991 | 8 | 0.090 |
Why?
|
| Jejunal Diseases | 1 | 1991 | 15 | 0.090 |
Why?
|
| Time Factors | 3 | 2010 | 6351 | 0.090 |
Why?
|
| Prognosis | 2 | 2017 | 4690 | 0.090 |
Why?
|
| Kidney | 1 | 2017 | 1369 | 0.090 |
Why?
|
| Middle Aged | 6 | 2020 | 27000 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2010 | 3470 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2008 | 2109 | 0.080 |
Why?
|
| Melanoma | 1 | 2017 | 944 | 0.080 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2009 | 51 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 1106 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2009 | 159 | 0.080 |
Why?
|
| Male | 9 | 2020 | 61776 | 0.080 |
Why?
|
| Hospitalization | 1 | 2017 | 1790 | 0.080 |
Why?
|
| Azathioprine | 1 | 2008 | 54 | 0.080 |
Why?
|
| Prednisolone | 1 | 2008 | 74 | 0.080 |
Why?
|
| Biomarkers | 3 | 2020 | 3095 | 0.080 |
Why?
|
| Adult | 7 | 2020 | 29734 | 0.070 |
Why?
|
| DNA, Viral | 1 | 2009 | 480 | 0.070 |
Why?
|
| Creatinine | 1 | 2010 | 391 | 0.070 |
Why?
|
| Filgrastim | 1 | 2007 | 15 | 0.070 |
Why?
|
| Dipeptidases | 1 | 2007 | 14 | 0.070 |
Why?
|
| Risk Factors | 2 | 2013 | 10340 | 0.070 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2007 | 96 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 1659 | 0.070 |
Why?
|
| Recurrence | 1 | 2010 | 1420 | 0.060 |
Why?
|
| Incidence | 1 | 2013 | 3155 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2007 | 340 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 1410 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 1991 | 1026 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2008 | 1568 | 0.050 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2002 | 46 | 0.050 |
Why?
|
| Female | 7 | 2020 | 66998 | 0.050 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2002 | 74 | 0.050 |
Why?
|
| Aged | 4 | 2017 | 19900 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2014 | 4585 | 0.050 |
Why?
|
| Liver Failure, Acute | 1 | 2002 | 89 | 0.050 |
Why?
|
| Dermatologists | 1 | 2021 | 3 | 0.050 |
Why?
|
| Hepatitis B Vaccines | 1 | 2021 | 42 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2021 | 104 | 0.040 |
Why?
|
| Young Adult | 2 | 2017 | 9093 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2017 | 51 | 0.030 |
Why?
|
| Steroids | 1 | 2017 | 203 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2007 | 2434 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1632 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 493 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2899 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 1278 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 2089 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2020 | 16417 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 1991 | 240 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 1991 | 241 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 5195 | 0.020 |
Why?
|
| Ligation | 1 | 2007 | 134 | 0.020 |
Why?
|
| Bile Ducts | 1 | 2007 | 53 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 436 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2007 | 381 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2007 | 781 | 0.020 |
Why?
|
| Rats | 1 | 2007 | 3728 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 19441 | 0.010 |
Why?
|
| Animals | 1 | 2007 | 34349 | 0.000 |
Why?
|